BQS OBSP Determination: |
1,7-DIMETHYLXANTHINE (P-XANTHINE) |
METHOD: 2440 , TESTIDCODE: 67446LCM56 |
Open Data Set |
Plotted Points Statistics |
1,7-DIMETHYLXANTHINE (P-XANTHINE) |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 79% | . | 79% | 0% |
>= Reporting Level | 73 | 114% | 33% | 113% | 38% |
Total | 74 | 113% | 33% | 112% | 39% |
Sample Statistics |
1,7-DIMETHYLXANTHINE (P-XANTHINE) |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 97% | Spiked |
Estimated Values | 27 | 36% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 76 | . | |
False Negatives | 1 | 1% | 1 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
BQS OBSP Determination: |
10-HYDROXY-AMITRIPTYLINE |
METHOD: 2440 , TESTIDCODE: 67995LCM56 |
Open Data Set |
Plotted Points Statistics |
10-HYDROXY-AMITRIPTYLINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 77% | 30% | 77% | 31% |
>= Reporting Level | 51 | 69% | 22% | 67% | 22% |
Total | 53 | 69% | 22% | 67% | 22% |
Sample Statistics |
10-HYDROXY-AMITRIPTYLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 53 | 100% | Spiked |
Estimated Values | 38 | 72% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 53 | . | |
False Negatives | 0 | 0% | 0 out of 53 |
Not Spiked | 62 | . | |
False Positives | 0 | 0% | 0 out of 62 |
Plotted Points Statistics |
ABACAVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 56% | 3% | 56% | 3% |
>= Reporting Level | 72 | 56% | 15% | 60% | 13% |
Total | 74 | 56% | 15% | 60% | 12% |
Sample Statistics |
ABACAVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 99% | Spiked |
Estimated Values | 4 | 5% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 1 | 1% | 1 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
ACETAMINOPHEN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 3 | 75% | 22% | 85% | 29% |
>= Reporting Level | 60 | 94% | 85% | 83% | 13% |
Total | 63 | 93% | 83% | 84% | 13% |
Sample Statistics |
ACETAMINOPHEN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 63 | 83% | Spiked |
Estimated Values | 8 | 11% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 10 | 13% | Spiked |
Spiked | 76 | . | |
False Negatives | 3 | 4% | 3 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
ACYCLOVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 336% | . | 336% | 0% |
>= Reporting Level | 60 | 176% | 113% | 168% | 143% |
Total | 61 | 179% | 114% | 170% | 144% |
Sample Statistics |
ACYCLOVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 61 | 81% | Spiked |
Estimated Values | 10 | 13% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 5% | Spiked |
Spiked | 75 | . | |
False Negatives | 10 | 13% | 10 out of 75 |
Not Spiked | 40 | . | |
False Positives | 21 | 53% | 21 out of 40 |
Plotted Points Statistics |
ALBUTEROL (SALBUTAMOL) |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 87% | . | 87% | 0% |
>= Reporting Level | 74 | 76% | 15% | 77% | 13% |
Total | 75 | 76% | 15% | 77% | 14% |
Sample Statistics |
ALBUTEROL (SALBUTAMOL) |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 99% | Spiked |
Estimated Values | 9 | 12% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 76 | . | |
False Negatives | 0 | 0% | 0 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
ALPRAZOLAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 74% | 51% | 74% | 54% |
>= Reporting Level | 47 | 80% | 14% | 78% | 13% |
Total | 49 | 80% | 15% | 78% | 13% |
Sample Statistics |
ALPRAZOLAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 49 | 98% | Spiked |
Estimated Values | 12 | 24% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 50 | . | |
False Negatives | 1 | 2% | 1 out of 50 |
Not Spiked | 65 | . | |
False Positives | 12 | 18% | 12 out of 65 |
Plotted Points Statistics |
AMITRIPTYLINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 27% | 21% | 27% | 22% |
>= Reporting Level | 73 | 55% | 14% | 56% | 13% |
Total | 75 | 54% | 14% | 55% | 14% |
Sample Statistics |
AMITRIPTYLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 100% | Spiked |
Estimated Values | 75 | 100% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 0 | 0% | 0 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
AMPHETAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 71% | . | 71% | 0% |
>= Reporting Level | 49 | 75% | 12% | 76% | 10% |
Total | 50 | 75% | 12% | 75% | 10% |
Sample Statistics |
AMPHETAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 50 | 98% | Spiked |
Estimated Values | 11 | 22% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 2% | Spiked |
Spiked | 51 | . | |
False Negatives | 0 | 0% | 0 out of 51 |
Not Spiked | 64 | . | |
False Positives | 0 | 0% | 0 out of 64 |
Plotted Points Statistics |
ANTIPYRENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 68% | 18% | 68% | 19% |
>= Reporting Level | 74 | 80% | 11% | 79% | 10% |
Total | 76 | 79% | 12% | 79% | 10% |
Sample Statistics |
ANTIPYRENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 100% | Spiked |
Estimated Values | 5 | 7% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 76 | . | |
False Negatives | 0 | 0% | 0 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
ATENOLOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 63 | 72% | 17% | 74% | 12% |
Total | 63 | 72% | 17% | 74% | 12% |
Sample Statistics |
ATENOLOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 63 | 81% | Spiked |
Estimated Values | 4 | 5% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 5 | 6% | Spiked |
Spiked | 78 | . | |
False Negatives | 10 | 13% | 10 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
ATRAZINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 70% | 1% | 70% | 1% |
>= Reporting Level | 73 | 79% | 12% | 77% | 10% |
Total | 75 | 79% | 12% | 77% | 12% |
Sample Statistics |
ATRAZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 99% | Spiked |
Estimated Values | 3 | 4% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 76 | . | |
False Negatives | 1 | 1% | 1 out of 76 |
Not Spiked | 39 | . | |
False Positives | 5 | 13% | 5 out of 39 |
Plotted Points Statistics |
BENZTROPINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 173% | . | 173% | 0% |
>= Reporting Level | 53 | 57% | 21% | 52% | 20% |
Total | 54 | 59% | 26% | 52% | 22% |
Sample Statistics |
BENZTROPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 54 | 72% | Spiked |
Estimated Values | 54 | 72% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 3 | 4% | Spiked |
Spiked | 75 | . | |
False Negatives | 18 | 24% | 18 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
BETAMETHASONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 34% | 14% | 34% | 14% |
>= Reporting Level | 72 | 87% | 18% | 87% | 19% |
Total | 74 | 86% | 20% | 87% | 19% |
Sample Statistics |
BETAMETHASONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 99% | Spiked |
Estimated Values | 24 | 32% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 1 | 1% | 1 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
BUPROPION |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 74% | 5% | 74% | 5% |
>= Reporting Level | 74 | 70% | 13% | 69% | 13% |
Total | 76 | 70% | 13% | 70% | 12% |
Sample Statistics |
BUPROPION |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 100% | Spiked |
Estimated Values | 1 | 1% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 76 | . | |
False Negatives | 0 | 0% | 0 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
CAFFEINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 77 | 82% | 18% | 81% | 10% |
Total | 77 | 82% | 18% | 81% | 10% |
Sample Statistics |
CAFFEINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 77 | 99% | Spiked |
Estimated Values | 26 | 33% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 78 | . | |
False Negatives | 0 | 0% | 0 out of 78 |
Not Spiked | 37 | . | |
False Positives | 3 | 8% | 3 out of 37 |
Plotted Points Statistics |
CARBAMAZEPINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 15 | 71% | 12% | 71% | 13% |
>= Reporting Level | 61 | 78% | 11% | 78% | 8% |
Total | 76 | 77% | 11% | 77% | 9% |
Sample Statistics |
CARBAMAZEPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 99% | Spiked |
Estimated Values | 5 | 6% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 77 | . | |
False Negatives | 0 | 0% | 0 out of 77 |
Not Spiked | 38 | . | |
False Positives | 1 | 3% | 1 out of 38 |
Plotted Points Statistics |
CARISOPRODOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 6 | 81% | 12% | 83% | 11% |
>= Reporting Level | 57 | 76% | 11% | 77% | 10% |
Total | 63 | 77% | 11% | 78% | 10% |
Sample Statistics |
CARISOPRODOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 63 | 97% | Spiked |
Estimated Values | 7 | 11% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 65 | . | |
False Negatives | 2 | 3% | 2 out of 65 |
Not Spiked | 50 | . | |
False Positives | 1 | 2% | 1 out of 50 |
Plotted Points Statistics |
CHLORPHENIRAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 12 | 46% | 15% | 43% | 11% |
>= Reporting Level | 32 | 42% | 12% | 40% | 12% |
Total | 44 | 43% | 12% | 41% | 12% |
Sample Statistics |
CHLORPHENIRAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 44 | 69% | Spiked |
Estimated Values | 25 | 39% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 64 | . | |
False Negatives | 20 | 31% | 20 out of 64 |
Not Spiked | 51 | . | |
False Positives | 0 | 0% | 0 out of 51 |
Plotted Points Statistics |
CIMETIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 68% | . | 68% | 0% |
>= Reporting Level | 36 | 48% | 25% | 47% | 27% |
Total | 37 | 48% | 24% | 49% | 28% |
Sample Statistics |
CIMETIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 37 | 48% | Spiked |
Estimated Values | 37 | 48% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 6 | 8% | Spiked |
Spiked | 77 | . | |
False Negatives | 34 | 44% | 34 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
CITALOPRAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 61 | 52% | 21% | 50% | 14% |
Total | 61 | 52% | 21% | 50% | 14% |
Sample Statistics |
CITALOPRAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 61 | 91% | Spiked |
Estimated Values | 14 | 21% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 67 | . | |
False Negatives | 5 | 7% | 5 out of 67 |
Not Spiked | 48 | . | |
False Positives | 0 | 0% | 0 out of 48 |
Plotted Points Statistics |
CLONIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 73% | 14% | 73% | 14% |
>= Reporting Level | 73 | 83% | 13% | 81% | 11% |
Total | 75 | 82% | 13% | 81% | 11% |
Sample Statistics |
CLONIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 100% | Spiked |
Estimated Values | 21 | 28% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 0 | 0% | 0 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
CODEINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 51 | 82% | 18% | 81% | 16% |
Total | 51 | 82% | 18% | 81% | 16% |
Sample Statistics |
CODEINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 51 | 100% | Spiked |
Estimated Values | 6 | 12% | Spiked |
Deleted Values | 2 | 2% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 51 | . | |
False Negatives | 0 | 0% | 0 out of 51 |
Not Spiked | 64 | . | |
False Positives | 0 | 0% | 0 out of 62 |
Plotted Points Statistics |
COTININE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 76 | 80% | 13% | 79% | 14% |
Total | 76 | 80% | 13% | 79% | 14% |
Sample Statistics |
COTININE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 97% | Spiked |
Estimated Values | 14 | 18% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 2 | 3% | 2 out of 78 |
Not Spiked | 37 | . | |
False Positives | 4 | 11% | 4 out of 37 |
Plotted Points Statistics |
DEHYDRONIFEDIPINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 77 | 68% | 14% | 70% | 14% |
Total | 77 | 68% | 14% | 70% | 14% |
Sample Statistics |
DEHYDRONIFEDIPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 77 | 99% | Spiked |
Estimated Values | 21 | 27% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 1 | 1% | 1 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
DESMETHYLDILTIAZEM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 6 | 48% | 11% | 48% | 13% |
>= Reporting Level | 49 | 40% | 14% | 40% | 12% |
Total | 55 | 41% | 13% | 41% | 12% |
Sample Statistics |
DESMETHYLDILTIAZEM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 55 | 71% | Spiked |
Estimated Values | 55 | 71% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 6 | 8% | Spiked |
Spiked | 77 | . | |
False Negatives | 16 | 21% | 16 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
DESVENLAFAXINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 12 | 77% | 18% | 77% | 10% |
>= Reporting Level | 61 | 72% | 13% | 71% | 14% |
Total | 73 | 73% | 14% | 72% | 14% |
Sample Statistics |
DESVENLAFAXINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 73 | 97% | Spiked |
Estimated Values | 11 | 15% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 75 | . | |
False Negatives | 1 | 1% | 1 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
DEXTROMETHORPHAN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 50% | 14% | 50% | 15% |
>= Reporting Level | 73 | 64% | 12% | 63% | 13% |
Total | 75 | 63% | 12% | 62% | 13% |
Sample Statistics |
DEXTROMETHORPHAN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 100% | Spiked |
Estimated Values | 2 | 3% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 0 | 0% | 0 out of 75 |
Not Spiked | 40 | . | |
False Positives | 1 | 3% | 1 out of 40 |
Plotted Points Statistics |
DIAZEPAM (VALIUM) |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 56 | 76% | 19% | 75% | 20% |
Total | 56 | 76% | 19% | 75% | 20% |
Sample Statistics |
DIAZEPAM (VALIUM) |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 56 | 89% | Spiked |
Estimated Values | 3 | 5% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 3 | 5% | Spiked |
Spiked | 63 | . | |
False Negatives | 4 | 6% | 4 out of 63 |
Not Spiked | 52 | . | |
False Positives | 0 | 0% | 0 out of 52 |
Plotted Points Statistics |
DILTIAZEM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 61 | 59% | 14% | 59% | 11% |
Total | 61 | 59% | 14% | 59% | 11% |
Sample Statistics |
DILTIAZEM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 61 | 97% | Spiked |
Estimated Values | 4 | 6% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 63 | . | |
False Negatives | 2 | 3% | 2 out of 63 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
DIPHENHYDRAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 6 | 92% | 31% | 82% | 37% |
>= Reporting Level | 56 | 70% | 10% | 69% | 10% |
Total | 62 | 72% | 14% | 69% | 10% |
Sample Statistics |
DIPHENHYDRAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 62 | 82% | Spiked |
Estimated Values | 24 | 32% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 5% | Spiked |
Spiked | 76 | . | |
False Negatives | 10 | 13% | 10 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
DULOXETINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 59 | 53% | 15% | 53% | 12% |
Total | 59 | 53% | 15% | 53% | 12% |
Sample Statistics |
DULOXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 59 | 89% | Spiked |
Estimated Values | 55 | 83% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 66 | . | |
False Negatives | 5 | 8% | 5 out of 66 |
Not Spiked | 49 | . | |
False Positives | 0 | 0% | 0 out of 49 |
Plotted Points Statistics |
ERYTHROMYCIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 31 | 37% | 18% | 37% | 24% |
Total | 31 | 37% | 18% | 37% | 24% |
Sample Statistics |
ERYTHROMYCIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 31 | 40% | Spiked |
Estimated Values | 10 | 13% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 8 | 10% | Spiked |
Spiked | 77 | . | |
False Negatives | 38 | 49% | 38 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
EZETIMIBE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 63% | 3% | 63% | 4% |
>= Reporting Level | 48 | 60% | 40% | 50% | 30% |
Total | 50 | 60% | 39% | 54% | 30% |
Sample Statistics |
EZETIMIBE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 50 | 66% | Spiked |
Estimated Values | 50 | 66% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 10 | 13% | Spiked |
Spiked | 76 | . | |
False Negatives | 16 | 21% | 16 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
FADROZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 76 | 62% | 11% | 60% | 11% |
Total | 76 | 62% | 11% | 60% | 11% |
Sample Statistics |
FADROZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 99% | Spiked |
Estimated Values | 5 | 6% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 77 | . | |
False Negatives | 1 | 1% | 1 out of 77 |
Not Spiked | 38 | . | |
False Positives | 2 | 5% | 2 out of 38 |
Plotted Points Statistics |
FAMOTIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 62% | 4% | 62% | 4% |
>= Reporting Level | 39 | 55% | 56% | 45% | 35% |
Total | 41 | 55% | 55% | 45% | 35% |
Sample Statistics |
FAMOTIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 41 | 55% | Spiked |
Estimated Values | 41 | 55% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 13 | 17% | Spiked |
Spiked | 75 | . | |
False Negatives | 21 | 28% | 21 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
FENOFIBRATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 44 | 49% | 22% | 47% | 21% |
Total | 44 | 49% | 22% | 47% | 21% |
Sample Statistics |
FENOFIBRATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 44 | 57% | Spiked |
Estimated Values | 31 | 40% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 6 | 8% | Spiked |
Spiked | 77 | . | |
False Negatives | 27 | 35% | 27 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
FEXOFENADINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 7 | 71% | 16% | 71% | 17% |
>= Reporting Level | 65 | 61% | 9% | 61% | 8% |
Total | 72 | 62% | 10% | 61% | 8% |
Sample Statistics |
FEXOFENADINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 72 | 95% | Spiked |
Estimated Values | 17 | 22% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 76 | . | |
False Negatives | 3 | 4% | 3 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
FLUCONAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 80% | 13% | 80% | 14% |
>= Reporting Level | 72 | 83% | 16% | 83% | 15% |
Total | 74 | 83% | 16% | 83% | 15% |
Sample Statistics |
FLUCONAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 99% | Spiked |
Estimated Values | 6 | 8% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 1 | 1% | 1 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
FLUOXETINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 75 | 60% | 14% | 57% | 11% |
Total | 75 | 60% | 14% | 57% | 11% |
Sample Statistics |
FLUOXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 96% | Spiked |
Estimated Values | 65 | 83% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 3 | 4% | 3 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
FLUTICASONE PROPIONATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 133% | . | 133% | 0% |
>= Reporting Level | 56 | 67% | 21% | 68% | 19% |
Total | 57 | 68% | 23% | 68% | 20% |
Sample Statistics |
FLUTICASONE PROPIONATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 57 | 88% | Spiked |
Estimated Values | 14 | 22% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 6% | Spiked |
Spiked | 65 | . | |
False Negatives | 4 | 6% | 4 out of 65 |
Not Spiked | 50 | . | |
False Positives | 0 | 0% | 0 out of 50 |
Plotted Points Statistics |
FLUVOXAMINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 75 | 43% | 15% | 43% | 15% |
Total | 75 | 43% | 15% | 43% | 15% |
Sample Statistics |
FLUVOXAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 96% | Spiked |
Estimated Values | 75 | 96% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 3 | 4% | 3 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Sample Statistics |
GABAPENTIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 4 | . | |
False Positives | 0 | 0% | 0 out of 4 |
Plotted Points Statistics |
GLIPIZIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 94% | . | 94% | 0% |
>= Reporting Level | 51 | 90% | 18% | 92% | 19% |
Total | 52 | 90% | 18% | 92% | 18% |
Sample Statistics |
GLIPIZIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 52 | 68% | Spiked |
Estimated Values | 27 | 35% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 24 | 31% | Spiked |
Spiked | 77 | . | |
False Negatives | 1 | 1% | 1 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
GLYBURIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 10 | 70% | 8% | 69% | 5% |
>= Reporting Level | 60 | 67% | 19% | 70% | 15% |
Total | 70 | 68% | 17% | 69% | 13% |
Sample Statistics |
GLYBURIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 70 | 92% | Spiked |
Estimated Values | 15 | 20% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 76 | . | |
False Negatives | 4 | 5% | 4 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Sample Statistics |
GUANYLUREA |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 4 | . | |
False Positives | 0 | 0% | 0 out of 4 |
Sample Statistics |
HEXAMETHYLENETETRAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 4 | . | |
False Positives | 3 | 75% | 3 out of 4 |
Plotted Points Statistics |
HYDROCODONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 44 | 77% | 19% | 76% | 16% |
Total | 44 | 77% | 19% | 76% | 16% |
Sample Statistics |
HYDROCODONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 44 | 86% | Spiked |
Estimated Values | 17 | 33% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 8% | Spiked |
Spiked | 51 | . | |
False Negatives | 3 | 6% | 3 out of 51 |
Not Spiked | 64 | . | |
False Positives | 0 | 0% | 0 out of 64 |
Plotted Points Statistics |
HYDROCORTISONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 67 | 83% | 12% | 82% | 10% |
Total | 67 | 83% | 12% | 82% | 10% |
Sample Statistics |
HYDROCORTISONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 67 | 89% | Spiked |
Estimated Values | 26 | 35% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 75 | . | |
False Negatives | 6 | 8% | 6 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
HYDROXYZINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 7% | . | 7% | 0% |
>= Reporting Level | 73 | 117% | 126% | 70% | 12% |
Total | 74 | 115% | 126% | 70% | 13% |
Sample Statistics |
HYDROXYZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 96% | Spiked |
Estimated Values | 6 | 8% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 77 | . | |
False Negatives | 2 | 3% | 2 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
IMINOSTILBENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 77 | 77% | 26% | 74% | 27% |
Total | 77 | 77% | 26% | 74% | 27% |
Sample Statistics |
IMINOSTILBENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 77 | 100% | Spiked |
Estimated Values | 11 | 14% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 77 | . | |
False Negatives | 0 | 0% | 0 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
KETOCONAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 39% | 7% | 39% | 7% |
>= Reporting Level | 70 | 46% | 16% | 46% | 16% |
Total | 72 | 46% | 16% | 45% | 15% |
Sample Statistics |
KETOCONAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 72 | 96% | Spiked |
Estimated Values | 29 | 39% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 3 | 4% | 3 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
LAMIVUDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 56 | 74% | 29% | 72% | 21% |
Total | 56 | 74% | 29% | 72% | 21% |
Sample Statistics |
LAMIVUDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 56 | 74% | Spiked |
Estimated Values | 18 | 24% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 3 | 4% | Spiked |
Spiked | 76 | . | |
False Negatives | 17 | 22% | 17 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
LIDOCAINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 6 | 98% | 17% | 95% | 17% |
>= Reporting Level | 66 | 84% | 12% | 83% | 9% |
Total | 72 | 85% | 13% | 83% | 10% |
Sample Statistics |
LIDOCAINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 72 | 95% | Spiked |
Estimated Values | 4 | 5% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 5% | Spiked |
Spiked | 76 | . | |
False Negatives | 0 | 0% | 0 out of 76 |
Not Spiked | 39 | . | |
False Positives | 1 | 3% | 1 out of 39 |
Plotted Points Statistics |
LOPERAMIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 12 | 53% | 15% | 45% | 19% |
>= Reporting Level | 28 | 44% | 17% | 45% | 18% |
Total | 40 | 47% | 17% | 45% | 17% |
Sample Statistics |
LOPERAMIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 40 | 63% | Spiked |
Estimated Values | 40 | 63% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 63 | . | |
False Negatives | 21 | 33% | 21 out of 63 |
Not Spiked | 52 | . | |
False Positives | 0 | 0% | 0 out of 52 |
Plotted Points Statistics |
LORATADINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 78 | 44% | 13% | 44% | 12% |
Total | 78 | 44% | 13% | 44% | 12% |
Sample Statistics |
LORATADINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 78 | 100% | Spiked |
Estimated Values | 38 | 49% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 0 | 0% | 0 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
LORAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 49 | 106% | 27% | 104% | 19% |
Total | 49 | 106% | 27% | 104% | 19% |
Sample Statistics |
LORAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 49 | 96% | Spiked |
Estimated Values | 28 | 55% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 4% | Spiked |
Spiked | 51 | . | |
False Negatives | 0 | 0% | 0 out of 51 |
Not Spiked | 64 | . | |
False Positives | 0 | 0% | 0 out of 64 |
Plotted Points Statistics |
MEPROBAMATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 86% | 26% | 86% | 27% |
>= Reporting Level | 48 | 86% | 12% | 85% | 11% |
Total | 50 | 86% | 12% | 85% | 11% |
Sample Statistics |
MEPROBAMATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 50 | 100% | Spiked |
Estimated Values | 4 | 8% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 50 | . | |
False Negatives | 0 | 0% | 0 out of 50 |
Not Spiked | 65 | . | |
False Positives | 0 | 0% | 0 out of 65 |
Plotted Points Statistics |
METAXALONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 66 | 62% | 23% | 68% | 17% |
Total | 66 | 62% | 23% | 68% | 17% |
Sample Statistics |
METAXALONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 66 | 85% | Spiked |
Estimated Values | 59 | 76% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 78 | . | |
False Negatives | 10 | 13% | 10 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
METFORMIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 76 | 61% | 17% | 61% | 17% |
Total | 76 | 61% | 17% | 61% | 17% |
Sample Statistics |
METFORMIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 97% | Spiked |
Estimated Values | 8 | 10% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 2 | 3% | 2 out of 78 |
Not Spiked | 37 | . | |
False Positives | 1 | 3% | 1 out of 37 |
Plotted Points Statistics |
METHADONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 47 | 68% | 16% | 64% | 10% |
Total | 47 | 68% | 16% | 64% | 10% |
Sample Statistics |
METHADONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 47 | 92% | Spiked |
Estimated Values | 6 | 12% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 4% | Spiked |
Spiked | 51 | . | |
False Negatives | 2 | 4% | 2 out of 51 |
Not Spiked | 64 | . | |
False Positives | 0 | 0% | 0 out of 64 |
Plotted Points Statistics |
METHOCARBAMOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 71 | 80% | 15% | 77% | 15% |
Total | 71 | 80% | 15% | 77% | 15% |
Sample Statistics |
METHOCARBAMOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 71 | 91% | Spiked |
Estimated Values | 9 | 12% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 3 | 4% | Spiked |
Spiked | 78 | . | |
False Negatives | 4 | 5% | 4 out of 78 |
Not Spiked | 37 | . | |
False Positives | 1 | 3% | 1 out of 37 |
Plotted Points Statistics |
METHOTREXATE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 60 | 56% | 18% | 53% | 18% |
Total | 60 | 56% | 18% | 53% | 18% |
Sample Statistics |
METHOTREXATE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 60 | 78% | Spiked |
Estimated Values | 52 | 68% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 77 | . | |
False Negatives | 15 | 19% | 15 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
METHYL-1H-BENZOTRIAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 95% | 6% | 95% | 7% |
>= Reporting Level | 74 | 85% | 11% | 83% | 8% |
Total | 76 | 85% | 11% | 84% | 9% |
Sample Statistics |
METHYL-1H-BENZOTRIAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 100% | Spiked |
Estimated Values | 13 | 17% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 76 | . | |
False Negatives | 0 | 0% | 0 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
METOPROLOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 32% | 4% | 32% | 5% |
>= Reporting Level | 71 | 36% | 5% | 35% | 5% |
Total | 73 | 36% | 5% | 35% | 4% |
Sample Statistics |
METOPROLOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 73 | 97% | Spiked |
Estimated Values | 4 | 5% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 75 | . | |
False Negatives | 1 | 1% | 1 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
MORPHINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 10 | 109% | 68% | 82% | 13% |
>= Reporting Level | 29 | 80% | 27% | 75% | 10% |
Total | 39 | 87% | 43% | 76% | 13% |
Sample Statistics |
MORPHINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 39 | 76% | Spiked |
Estimated Values | 3 | 6% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 4% | Spiked |
Spiked | 51 | . | |
False Negatives | 10 | 20% | 10 out of 51 |
Not Spiked | 64 | . | |
False Positives | 0 | 0% | 0 out of 64 |
Plotted Points Statistics |
NADALOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 76% | 18% | 76% | 19% |
>= Reporting Level | 74 | 81% | 17% | 77% | 13% |
Total | 76 | 81% | 17% | 77% | 13% |
Sample Statistics |
NADALOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 100% | Spiked |
Estimated Values | 8 | 11% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 76 | . | |
False Negatives | 0 | 0% | 0 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
NEVIRAPINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 12 | 82% | 14% | 80% | 9% |
>= Reporting Level | 63 | 78% | 13% | 76% | 11% |
Total | 75 | 78% | 13% | 76% | 11% |
Sample Statistics |
NEVIRAPINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 100% | Spiked |
Estimated Values | 6 | 8% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 75 | . | |
False Negatives | 0 | 0% | 0 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
NICOTINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 72 | 52% | 26% | 47% | 22% |
Total | 72 | 52% | 26% | 47% | 22% |
Sample Statistics |
NICOTINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 72 | 94% | Spiked |
Estimated Values | 22 | 29% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 77 | . | |
False Negatives | 3 | 4% | 3 out of 77 |
Not Spiked | 38 | . | |
False Positives | 3 | 8% | 3 out of 38 |
Plotted Points Statistics |
NIZATIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 3 | 49% | 33% | 67% | 43% |
>= Reporting Level | 35 | 35% | 21% | 34% | 27% |
Total | 38 | 37% | 22% | 34% | 30% |
Sample Statistics |
NIZATIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 38 | 49% | Spiked |
Estimated Values | 38 | 49% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 3 | 4% | Spiked |
Spiked | 77 | . | |
False Negatives | 36 | 47% | 36 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
NORDIAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 52 | 81% | 7% | 80% | 8% |
Total | 52 | 81% | 7% | 80% | 8% |
Sample Statistics |
NORDIAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 52 | 100% | Spiked |
Estimated Values | 11 | 21% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 52 | . | |
False Negatives | 0 | 0% | 0 out of 52 |
Not Spiked | 63 | . | |
False Positives | 0 | 0% | 0 out of 63 |
Plotted Points Statistics |
NORETHINDRONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 67 | 74% | 17% | 73% | 13% |
Total | 67 | 74% | 17% | 73% | 13% |
Sample Statistics |
NORETHINDRONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 67 | 89% | Spiked |
Estimated Values | 8 | 11% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 6 | 8% | Spiked |
Spiked | 75 | . | |
False Negatives | 2 | 3% | 2 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
NORFLUOXETINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 69 | 60% | 14% | 58% | 15% |
Total | 69 | 60% | 14% | 58% | 15% |
Sample Statistics |
NORFLUOXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 69 | 100% | Spiked |
Estimated Values | 65 | 94% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 69 | . | |
False Negatives | 0 | 0% | 0 out of 69 |
Not Spiked | 46 | . | |
False Positives | 0 | 0% | 0 out of 46 |
Plotted Points Statistics |
NORSERTRALINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 26 | 53% | 12% | 51% | 10% |
Total | 26 | 53% | 12% | 51% | 10% |
Sample Statistics |
NORSERTRALINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 26 | 93% | Spiked |
Estimated Values | 26 | 93% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 28 | . | |
False Negatives | 2 | 7% | 2 out of 28 |
Not Spiked | 87 | . | |
False Positives | 0 | 0% | 0 out of 87 |
Plotted Points Statistics |
NORVERAPAMIL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 13% | . | 13% | 0% |
>= Reporting Level | 53 | 39% | 19% | 36% | 13% |
Total | 54 | 38% | 19% | 35% | 13% |
Sample Statistics |
NORVERAPAMIL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 54 | 82% | Spiked |
Estimated Values | 54 | 82% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 66 | . | |
False Negatives | 10 | 15% | 10 out of 66 |
Not Spiked | 49 | . | |
False Positives | 0 | 0% | 0 out of 49 |
BQS OBSP Determination: |
OMEPRAZOLE + ESOMEPRAZOLE |
METHOD: 2440 , TESTIDCODE: 67512LCM56 |
Open Data Set |
Plotted Points Statistics |
OMEPRAZOLE + ESOMEPRAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 4 | 29% | 2% | 29% | 2% |
>= Reporting Level | 32 | 30% | 15% | 28% | 8% |
Total | 36 | 30% | 14% | 28% | 7% |
Sample Statistics |
OMEPRAZOLE + ESOMEPRAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 36 | 48% | Spiked |
Estimated Values | 12 | 16% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 9 | 12% | Spiked |
Spiked | 75 | . | |
False Negatives | 30 | 40% | 30 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
OSELTAMIVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 57 | 51% | 12% | 51% | 10% |
Total | 57 | 51% | 12% | 51% | 10% |
Sample Statistics |
OSELTAMIVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 57 | 92% | Spiked |
Estimated Values | 10 | 16% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 62 | . | |
False Negatives | 3 | 5% | 3 out of 62 |
Not Spiked | 53 | . | |
False Positives | 0 | 0% | 0 out of 53 |
Plotted Points Statistics |
OXAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 44 | 63% | 29% | 53% | 39% |
Total | 44 | 63% | 29% | 53% | 39% |
Sample Statistics |
OXAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 44 | 85% | Spiked |
Estimated Values | 19 | 37% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 4% | Spiked |
Spiked | 52 | . | |
False Negatives | 6 | 12% | 6 out of 52 |
Not Spiked | 63 | . | |
False Positives | 0 | 0% | 0 out of 63 |
Plotted Points Statistics |
OXYCODONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 47 | 77% | 17% | 75% | 14% |
Total | 47 | 77% | 17% | 75% | 14% |
Sample Statistics |
OXYCODONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 47 | 94% | Spiked |
Estimated Values | 7 | 14% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 4% | Spiked |
Spiked | 50 | . | |
False Negatives | 1 | 2% | 1 out of 50 |
Not Spiked | 65 | . | |
False Positives | 0 | 0% | 0 out of 65 |
Plotted Points Statistics |
PAROXETINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 10 | 64% | 15% | 60% | 10% |
>= Reporting Level | 59 | 45% | 14% | 46% | 13% |
Total | 69 | 48% | 16% | 48% | 14% |
Sample Statistics |
PAROXETINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 69 | 87% | Spiked |
Estimated Values | 69 | 87% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 79 | . | |
False Negatives | 10 | 13% | 10 out of 79 |
Not Spiked | 36 | . | |
False Positives | 0 | 0% | 0 out of 36 |
Plotted Points Statistics |
PENCICLOVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 142% | . | 142% | 0% |
>= Reporting Level | 63 | 85% | 30% | 76% | 35% |
Total | 64 | 86% | 31% | 76% | 35% |
Sample Statistics |
PENCICLOVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 64 | 84% | Spiked |
Estimated Values | 24 | 32% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 8 | 11% | Spiked |
Spiked | 76 | . | |
False Negatives | 4 | 5% | 4 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
PENTOXIFYLLINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 50% | 3% | 50% | 3% |
>= Reporting Level | 66 | 72% | 13% | 74% | 12% |
Total | 68 | 71% | 14% | 74% | 13% |
Sample Statistics |
PENTOXIFYLLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 68 | 88% | Spiked |
Estimated Values | 10 | 13% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 3 | 4% | Spiked |
Spiked | 77 | . | |
False Negatives | 6 | 8% | 6 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
PHENAZOPYRIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 77 | 78% | 19% | 76% | 17% |
Total | 77 | 78% | 19% | 76% | 17% |
Sample Statistics |
PHENAZOPYRIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 77 | 97% | Spiked |
Estimated Values | 21 | 27% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 79 | . | |
False Negatives | 0 | 0% | 0 out of 79 |
Not Spiked | 36 | . | |
False Positives | 0 | 0% | 0 out of 36 |
Sample Statistics |
PHENDIMETRAZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 115 | . | |
False Positives | 0 | 0% | 0 out of 115 |
Plotted Points Statistics |
PHENYTOIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 77 | 86% | 13% | 83% | 11% |
Total | 77 | 86% | 13% | 83% | 11% |
Sample Statistics |
PHENYTOIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 77 | 99% | Spiked |
Estimated Values | 19 | 24% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 1 | 1% | 1 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
PIPERONYL BUTOXIDE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 9 | 47% | 25% | 41% | 25% |
>= Reporting Level | 59 | 54% | 23% | 52% | 22% |
Total | 68 | 53% | 24% | 50% | 23% |
Sample Statistics |
PIPERONYL BUTOXIDE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 68 | 86% | Spiked |
Estimated Values | 35 | 44% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 5 | 6% | Spiked |
Spiked | 79 | . | |
False Negatives | 6 | 8% | 6 out of 79 |
Not Spiked | 36 | . | |
False Positives | 0 | 0% | 0 out of 36 |
Plotted Points Statistics |
PREDNISOLONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 98% | 26% | 98% | 27% |
>= Reporting Level | 72 | 78% | 13% | 76% | 12% |
Total | 74 | 79% | 14% | 77% | 12% |
Sample Statistics |
PREDNISOLONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 96% | Spiked |
Estimated Values | 19 | 25% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 77 | . | |
False Negatives | 3 | 4% | 3 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
PREDNISONE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 77 | 86% | 16% | 87% | 14% |
Total | 77 | 86% | 16% | 87% | 14% |
Sample Statistics |
PREDNISONE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 77 | 99% | Spiked |
Estimated Values | 35 | 45% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 1 | 1% | 1 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
PROMETHAZINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 11 | 20% | 8% | 18% | 13% |
Total | 11 | 20% | 8% | 18% | 13% |
Sample Statistics |
PROMETHAZINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 11 | 14% | Spiked |
Estimated Values | 11 | 14% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 5% | Spiked |
Spiked | 76 | . | |
False Negatives | 61 | 80% | 61 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
Plotted Points Statistics |
PROPOXYPHENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 19% | . | 19% | 0% |
>= Reporting Level | 60 | 66% | 21% | 60% | 13% |
Total | 61 | 65% | 22% | 59% | 13% |
Sample Statistics |
PROPOXYPHENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 61 | 97% | Spiked |
Estimated Values | 25 | 40% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 2% | Spiked |
Spiked | 63 | . | |
False Negatives | 1 | 2% | 1 out of 63 |
Not Spiked | 52 | . | |
False Positives | 0 | 0% | 0 out of 52 |
Plotted Points Statistics |
PROPRANOLOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 49% | . | 49% | 0% |
>= Reporting Level | 73 | 69% | 10% | 70% | 10% |
Total | 74 | 69% | 10% | 70% | 11% |
Sample Statistics |
PROPRANOLOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 97% | Spiked |
Estimated Values | 3 | 4% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 76 | . | |
False Negatives | 1 | 1% | 1 out of 76 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 39 |
BQS OBSP Determination: |
PSEUDOEPHEDRINE+EPHEDRINE |
METHOD: 2440 , TESTIDCODE: 67460LCM56 |
Open Data Set |
Plotted Points Statistics |
PSEUDOEPHEDRINE+EPHEDRINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 41 | 63% | 22% | 72% | 33% |
Total | 41 | 63% | 22% | 72% | 33% |
Sample Statistics |
PSEUDOEPHEDRINE+EPHEDRINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 41 | 100% | Spiked |
Estimated Values | 3 | 7% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 41 | . | |
False Negatives | 0 | 0% | 0 out of 41 |
Not Spiked | 74 | . | |
False Positives | 0 | 0% | 0 out of 74 |
Plotted Points Statistics |
QUININE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 77 | 66% | 18% | 63% | 16% |
Total | 77 | 66% | 18% | 63% | 16% |
Sample Statistics |
QUININE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 77 | 99% | Spiked |
Estimated Values | 32 | 41% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 1 | 1% | 1 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Sample Statistics |
RACTOPAMINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 0 | . | Spiked |
Estimated Values | 0 | . | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | . | Spiked |
Spiked | 0 | . | |
False Negatives | 0 | . | 0 out of 0 |
Not Spiked | 4 | . | |
False Positives | 0 | 0% | 0 out of 4 |
Plotted Points Statistics |
RALOXIFENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 10 | 46% | 17% | 46% | 22% |
>= Reporting Level | 50 | 45% | 47% | 34% | 23% |
Total | 60 | 45% | 43% | 36% | 22% |
Sample Statistics |
RALOXIFENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 60 | 80% | Spiked |
Estimated Values | 60 | 80% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 5% | Spiked |
Spiked | 75 | . | |
False Negatives | 11 | 15% | 11 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
RANITIDINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 44 | 34% | 18% | 39% | 20% |
Total | 44 | 34% | 18% | 39% | 20% |
Sample Statistics |
RANITIDINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 44 | 64% | Spiked |
Estimated Values | 44 | 64% | Spiked |
Deleted Values | 9 | 8% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 76 | . | |
False Negatives | 23 | 33% | 23 out of 69 |
Not Spiked | 39 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
SERTRALINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 67 | 44% | 12% | 45% | 11% |
Total | 67 | 44% | 12% | 45% | 11% |
Sample Statistics |
SERTRALINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 67 | 89% | Spiked |
Estimated Values | 67 | 89% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 75 | . | |
False Negatives | 6 | 8% | 6 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
SITAGLIPTIN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 104% | 34% | 104% | 36% |
>= Reporting Level | 61 | 74% | 20% | 74% | 15% |
Total | 63 | 75% | 21% | 74% | 16% |
Sample Statistics |
SITAGLIPTIN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 63 | 100% | Spiked |
Estimated Values | 21 | 33% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 63 | . | |
False Negatives | 0 | 0% | 0 out of 63 |
Not Spiked | 52 | . | |
False Positives | 0 | 0% | 0 out of 52 |
Plotted Points Statistics |
SULFADIMETHOXINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 78 | 82% | 16% | 82% | 13% |
Total | 78 | 82% | 16% | 82% | 13% |
Sample Statistics |
SULFADIMETHOXINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 78 | 100% | Spiked |
Estimated Values | 11 | 14% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 0 | 0% | 0 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |
Plotted Points Statistics |
SULFAMETHIZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 78 | 78% | 11% | 77% | 8% |
Total | 78 | 78% | 11% | 77% | 8% |
Sample Statistics |
SULFAMETHIZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 78 | 99% | Spiked |
Estimated Values | 5 | 6% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 79 | . | |
False Negatives | 1 | 1% | 1 out of 79 |
Not Spiked | 36 | . | |
False Positives | 0 | 0% | 0 out of 36 |
Plotted Points Statistics |
SULFAMETHOXAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 63% | . | 63% | 0% |
>= Reporting Level | 73 | 80% | 13% | 81% | 9% |
Total | 74 | 80% | 13% | 81% | 9% |
Sample Statistics |
SULFAMETHOXAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 74 | 99% | Spiked |
Estimated Values | 8 | 11% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 75 | . | |
False Negatives | 0 | 0% | 0 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
TAMOXIFEN |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 5 | 19% | 7% | 17% | 7% |
Total | 5 | 19% | 7% | 17% | 7% |
Sample Statistics |
TAMOXIFEN |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 5 | 7% | Spiked |
Estimated Values | 5 | 7% | Spiked |
Deleted Values | 7 | 6% | Spiked + Not Spiked |
Spiked, Censored | 5 | 7% | Spiked |
Spiked | 77 | . | |
False Negatives | 62 | 86% | 62 out of 72 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 36 |
Plotted Points Statistics |
TEMAZEPAM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 48 | 62% | 28% | 70% | 39% |
Total | 48 | 62% | 28% | 70% | 39% |
Sample Statistics |
TEMAZEPAM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 48 | 77% | Spiked |
Estimated Values | 4 | 6% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 10 | 16% | Spiked |
Spiked | 62 | . | |
False Negatives | 4 | 6% | 4 out of 62 |
Not Spiked | 53 | . | |
False Positives | 0 | 0% | 0 out of 53 |
Plotted Points Statistics |
THEOPHYLLINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 53 | 80% | 20% | 83% | 16% |
Total | 53 | 80% | 20% | 83% | 16% |
Sample Statistics |
THEOPHYLLINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 53 | 71% | Spiked |
Estimated Values | 12 | 16% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 11 | 15% | Spiked |
Spiked | 75 | . | |
False Negatives | 11 | 15% | 11 out of 75 |
Not Spiked | 40 | . | |
False Positives | 1 | 3% | 1 out of 40 |
Plotted Points Statistics |
THIABENDAZOLE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 2 | 83% | 2% | 83% | 2% |
>= Reporting Level | 57 | 74% | 19% | 74% | 12% |
Total | 59 | 74% | 19% | 74% | 13% |
Sample Statistics |
THIABENDAZOLE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 59 | 79% | Spiked |
Estimated Values | 20 | 27% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 4 | 5% | Spiked |
Spiked | 75 | . | |
False Negatives | 12 | 16% | 12 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
TIOTROPIUM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 3 | 33% | 2% | 32% | 4% |
>= Reporting Level | 41 | 33% | 27% | 28% | 24% |
Total | 44 | 33% | 26% | 30% | 23% |
Sample Statistics |
TIOTROPIUM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 44 | 85% | Spiked |
Estimated Values | 44 | 85% | Spiked |
Deleted Values | 1 | 1% | Spiked + Not Spiked |
Spiked, Censored | 2 | 4% | Spiked |
Spiked | 52 | . | |
False Negatives | 6 | 12% | 6 out of 52 |
Not Spiked | 63 | . | |
False Positives | 0 | 0% | 0 out of 62 |
Plotted Points Statistics |
TRAMADOL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 54 | 77% | 11% | 78% | 11% |
Total | 54 | 77% | 11% | 78% | 11% |
Sample Statistics |
TRAMADOL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 54 | 100% | Spiked |
Estimated Values | 4 | 7% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 54 | . | |
False Negatives | 0 | 0% | 0 out of 54 |
Not Spiked | 61 | . | |
False Positives | 0 | 0% | 0 out of 61 |
Plotted Points Statistics |
TRIAMTERENE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 76 | 74% | 14% | 74% | 13% |
Total | 76 | 74% | 14% | 74% | 13% |
Sample Statistics |
TRIAMTERENE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 76 | 99% | Spiked |
Estimated Values | 14 | 18% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 77 | . | |
False Negatives | 1 | 1% | 1 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
TRIMETHOPRIM |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 75 | 81% | 20% | 80% | 20% |
Total | 75 | 81% | 20% | 80% | 20% |
Sample Statistics |
TRIMETHOPRIM |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 75 | 97% | Spiked |
Estimated Values | 8 | 10% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 77 | . | |
False Negatives | 2 | 3% | 2 out of 77 |
Not Spiked | 38 | . | |
False Positives | 0 | 0% | 0 out of 38 |
Plotted Points Statistics |
VALACYCLOVIR |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
>= Reporting Level | 60 | 35% | 20% | 31% | 16% |
Total | 60 | 35% | 20% | 31% | 16% |
Sample Statistics |
VALACYCLOVIR |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 60 | 92% | Spiked |
Estimated Values | 60 | 92% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 2 | 3% | Spiked |
Spiked | 65 | . | |
False Negatives | 3 | 5% | 3 out of 65 |
Not Spiked | 50 | . | |
False Positives | 0 | 0% | 0 out of 50 |
Plotted Points Statistics |
VENLAFAXINE |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 1 | 64% | . | 64% | 0% |
>= Reporting Level | 68 | 64% | 13% | 63% | 14% |
Total | 69 | 64% | 13% | 63% | 14% |
Sample Statistics |
VENLAFAXINE |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 69 | 92% | Spiked |
Estimated Values | 4 | 5% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 1 | 1% | Spiked |
Spiked | 75 | . | |
False Negatives | 5 | 7% | 5 out of 75 |
Not Spiked | 40 | . | |
False Positives | 0 | 0% | 0 out of 40 |
Plotted Points Statistics |
VERAPAMIL |
Spike Level | N | Mean | Std-Dev. | Median | F_Pseudo |
---|---|---|---|---|---|
< Reporting Level | 10 | 48% | 36% | 32% | 18% |
>= Reporting Level | 59 | 34% | 15% | 30% | 15% |
Total | 69 | 36% | 20% | 30% | 15% |
Sample Statistics |
VERAPAMIL |
Characteristic | N | % | % Basis |
---|---|---|---|
Plotted | 69 | 88% | Spiked |
Estimated Values | 21 | 27% | Spiked |
Deleted Values | 0 | 0% | Spiked + Not Spiked |
Spiked, Censored | 0 | 0% | Spiked |
Spiked | 78 | . | |
False Negatives | 9 | 12% | 9 out of 78 |
Not Spiked | 37 | . | |
False Positives | 0 | 0% | 0 out of 37 |